OncoSec reports interim data from breast cancer trial
OncoSec Medical interim data from an ongoing Phase 2 study showed 50% of evaluated breast cancer patients experienced a 20% or greater tumor reduction. The study is looking at Tavo in combination with Keytruda in patients with heavily pretreated mTNBC. May 22, 2019